Page 30 - Wondergem

Chapter 1
107. NademanneeA,FormanS,MolinaAetla.Aphase1⁄2trialofhigh-doseYttrium-90-ibritumomabtiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patiens with poor risk or relapsed non-Hodgkin lymphoma. Blood 2005;106:2896-2902
108. Ibatici A, Pica GM, Nati S et al. Safety and efficacy of (90)Yttrium-ibritumomab tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol 2014;164(5):710-716
109. Morschhauser F, Radford J, Van Hoof A et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent trial. J Clin Oncol 2013;31(16):1977- 1983
110. WisemanGA,GordonLI,MultaniPSetal.Ibritumomabtiuxetanradioimmunotherapyforpatientswith relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99(12):4336-4342
111. Schilder R, Molina A, Barlett N et al. Follow-up results af a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade follicular or transformed B-cell non- Hodgkin’s lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2004;19(4):478-481
112. Zelenetz A, Saleh M, Vose J et al. Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and iodine I 131 tositumomab.(abstract) Blood 2002;100:357a
113. Tracey L, Pérez-Rosado A, Artiga MJ et al. Expression of the NF-kB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B cell lymphomas, respectively. J Pathol 2005;206:123-134
114. De Graaf AO, van Krieken JH, Tönnissen E et al. Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol 2005;130:852-859
115. Adida C, Haioun C, Gaulard P et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96:1921-1925
116. Tolcher AW, Mita A, Lewis LD, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008;26(32):5198-5203.
117. Kaneko N, Mitsuoka K, Amino N, et al. Combination of YM155, a survivin suppressant, with bendamustine and rituxima: a new combination therapy to treat
28